Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 5/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780938 | 0.86 | MAPK1 (0.48) | MAPK1MAP2K4KITFLT3CHEK1 | |
| SCHEMBL4783913 | 0.85 | PRKCZ (0.48) | MAPK1MAP2K4KITFLT3CHEK1 | |
| Lithium Ion SCHEMBL4783900 | 0.84 | MAPK1 (0.45) | MAPK1KITFLT3FGFR1 | |
| SCHEMBL4783741 | 0.79 | KIT (0.52) | KITFLT3KDM4EALDH1A1TSHR | |
| SCHEMBL4781301 | 0.78 | AURKA (0.54) | MAPK1KITFLT3FGFR1AURKA | |
| SCHEMBL4785037 | 0.78 | RAB9A (0.54) | KDM4EALDH1A1GAA | |
| SCHEMBL4781936 | 0.77 | FLT3 (0.52) | MAPK1KITFLT3FGFR1AURKA | |
| SCHEMBL4785283 | 0.77 | KDM4E (0.43) | KDM4EALDH1A1TSHRGAAWDR5 | |
| SCHEMBL4784235 | 0.77 | KMT2A (0.51) | KITAURKA | |
| SCHEMBL4784112 | 0.77 | ALDH1A1 (0.54) | MAPK1KITFLT3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| WO-2008061109-A2 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008061109-A2 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | MAPK1 3438/4885MAP2K4 4145/4885KIT 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.